Emerald Advisers, LLC Arvinas, Inc. Transaction History

Emerald Advisers, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$26.15 - $37.26 $5.1 Million - $7.27 Million	-195,067 Reduced 54.26%	164,416 $4.49 Million
Q4 2022 Feb 03, 2023	BUY	$32.47 - $57.24 $1.29 Million - $2.28 Million	39,746 Added 12.43%	359,483 $12.3 Million
Q3 2022 Oct 25, 2022	BUY	$41.87 - $57.99 $2.16 Million - $2.99 Million	51,481 Added 19.19%	319,737 $14.2 Million
Q2 2022 Jul 29, 2022	SELL	$36.01 - $74.24 $702,915 - $1.45 Million	-19,520 Reduced 6.78%	268,256 $11.3 Million
Q1 2022 Apr 29, 2022	SELL	$60.27 - $81.57 $1.83 Million - $2.48 Million	-30,399 Reduced 9.55%	287,776 $19.4 Million
Q4 2021 Feb 02, 2022	BUY	$65.85 - $96.21 $2.21 Million - $3.24 Million	33,634 Added 11.82%	318,175 $26.1 Million
Q3 2021 Oct 28, 2021	BUY	$73.2 - $107.87 $1.16 Million - $1.7 Million	15,779 Added 5.87%	284,541 $23.4 Million
Q2 2021 Jul 29, 2021	SELL	$60.45 - $84.26 $1.19 Million - $1.65 Million	-19,640 Reduced 6.81%	268,762 $20.7 Million
Q1 2021 Apr 29, 2021	BUY	$58.19 - $91.37 $1.77 Million - $2.78 Million	30,462 Added 11.81%	288,402 $19.1 Million
Q4 2020 Jan 29, 2021	BUY	$20.19 - $84.93 $5.21 Million - $21.9 Million	257,940 New	257,940 $21.9 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.